All In Biotech

Drug Trial Radar · NCT07540364

A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)

A Phase 3, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Samelisant Compared to Placebo in Patients With Narcolepsy With or Without Cataplexy

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Nov 19, 2027

Study completion Dec 19, 2027

Sponsor

Lead sponsor
Suven Life Sciences LimitedIndustry
Sponsor type
Industry
First posted
Apr 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effect of Samelisant on excessive daytime sleepiness (EDS) after 12 weeks of treatment. In addition, the study aims to assess its effectiveness in influencing the weekly frequency of cataplexy episodes (sudden bouts of muscle weakness) that occur while the individual remains conscious. Other objectives include examining the impact of Samelisant on attention and alertness, overall quality of life, the spectrum of narcolepsy symptoms, and daily functioning, as well as evaluating its safety profile.

Conditions

  • Narcolepsy

Interventions

  • SamelisantDrug

    Tablet dosage form, once a day

  • PlaceboDrug

    Matching placebo tablets, once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in total Epworth Sleepiness Scale (ESS) score at Week 12Time frame: Baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bogan Sleep Consultants

    Columbia, South Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.